News

December 1, 2016December 1, 2016

First Patient Enrolled in Phase 2 Trial of Therapy for Hypoxemia in IPF

Global Blood Therapeutics (GBT) recently announced it has enrolled the first patient into its Phase 2 ZEPHYR clinical trial (NCT02846324), assessing the safety and effectiveness of GBT440 in treating hypoxemia in ... Read more

November 30, 2016November 30, 2016

Smartinhaler Use Helps Children with Severe Asthma Stay with Treatments, Study Finds

Asthma, News

Adherium Limited announced promising results from a clinical trial evaluating the use of Smartinhaler, its respiratory disease management tool, in children with poorly controlled asthma. Over 12 months, Smartinhaler use was seen to significantly reduce ... Read more

November 29, 2016November 29, 2016

Blood Test Seen to Predict Chemotherapy Response in Advanced Lung Cancer Patients

Lung Cancer, News

Scientists at the Cancer Research UK Manchester Institute found that a simple blood test may tell how well patients with small-cell lung cancer (SCLC) will respond to chemotherapy. The study, “Molecular analysis ... Read more

November 28, 2016November 28, 2016

SteadyMed Launches Website, Social Media Campaign During Pulmonary Hypertension Awareness Month

News, Pulmonary Hypertension

SteadyMed recently announced the launch of BePHenomenal, a new website created to educate and empower people living with pulmonary hypertension (PH), a Thunderclap and a new social media campaign, #PHenomSelf, to recognize “strength ... Read more

November 23, 2016November 23, 2016

Bacteria’s Own Movement May Offer Way of Clearing It from Patients’ Lungs

News

An opportunistic bacteria linked to serious lung infections in immune-compromised patients unleashes a natural defense mechanism — called neutrophil extracellular traps (NETs) — by moving its “tail” during a relatively early growth stage, ... Read more

November 21, 2016November 21, 2016

Possible PAH Treatment, Now in Testing as Anti-Psychotic, Named Orphan Drug by FDA

News, Pulmonary Hypertension

Reviva Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to RP5063 as a potential treatment of pulmonary arterial hypertension (PAH). The product is already in clinical ... Read more

November 18, 2016November 18, 2016

ProMetic’s Therapy Improved Fibrosis, Cardiac Function in Mice with Heart Failure

News, Pulmonary Hypertension

ProMetic Life Science’s fibrosis-targeting investigational drug PBI-4050 improved pulmonary hypertension (PH), lung remodeling and right ventricular function in mice with heart failure. PBI-4050 also decreased biomarkers for heart disease in patients with ... Read more

November 17, 2016November 17, 2016

Multidrug-Resistant Bacterium in Cystic Fibrosis Patients Spreading Globally, Study Finds

Cystic Fibrosis, News

A study led by England’s University of Cambridge and the Wellcome Trust Sanger Institute showed that multidrug-resistant nontuberculous mycobacterium, known to cause serious complications in cystic fibrosis (CF) patients, has spread globally ... Read more

November 16, 2016November 16, 2016

Fetal Health Foundation Awards $50,000 to Researcher Working to Treat Birth Defect

News, Pulmonary Hypertension

The Fetal Health Foundation (FHF) named Dr. Jan Deprest the recipient of the 2016 Brianna Marie Memorial Research Grant, a $50,000 award that will be used to further his research ... Read more

November 15, 2016November 15, 2016

Enterprise Therapeutics Closes on $5 Million in Financing to Develop Mucus-clearing Therapies

Asthma, COPD, Cystic Fibrosis, News

Enterprise Therapeutics has closed on £4 million ($5 million U.S.) in financing to develop and advance its novel mucus-clearing therapies to treat patients with severe lung diseases. Enterprise is pursuing new ... Read more